What's new? Log in Free sign up

Royalty Pharma (RPRX)

Company Profile

Company profile

Ticker

RPRX

Exchange

Website

www.royaltypharma.com

CEO

Mr. Pablo Gerardo Legorreta

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Royalty Pharma Holdings Ltd • RPI 2019 Intermediate Finance • RPI Acquisitions (Ireland) Limited • RPI Finance • RP IP HoldCo (Ireland) Limited ...

RPRX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Additional proxy soliciting materials

Additional proxy soliciting materials

Business combination disclosure

Additional proxy soliciting materials

J.P. Morgan Healthcare Conference January 2025 2

Additional proxy soliciting materials

Entry into a Material Definitive Agreement

ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Entry into a Material Definitive Agreement

Quarterly report

6 Nov 24

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Bonnie L Bassler

Henry A Fernandez

Bonnie L Bassler

Henry A Fernandez

Terrance P. Coyne

George W. Lloyd

Severgnini Achille G.

Henry A Fernandez

Financial summary

Financial statements Chart RPRX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	950.05 mm	950.05 mm	950.05 mm	950.05 mm	950.05 mm	950.05 mm
Cash burn (monthly)	271.53 mm	(no burn)	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	1.16 bn	n/a	n/a	n/a	n/a	n/a
Cash remaining	-206.39 mm	n/a	n/a	n/a	n/a	n/a
Runway (months of cash)	-0.8	n/a	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

RPRX institutional ownership history Ownership history

88.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	389	374	+4.0%
Opened positions	59	62	-4.8%
Closed positions	44	58	-24.1%
Increased positions	157	138	+13.8%
Reduced positions	119	124	-4.0%

13F shares	Current	Prev Q	Change
Total value	8.57 tn	8.19 tn	+4.6%
Total shares	392.85 mm	359.72 mm	+9.2%
Total puts	47.50 k	138.20 k	-65.6%
Total calls	577.50 k	304.70 k	+89.5%
Total put/call ratio	0.1	0.5	-81.9%

Largest owners	Shares	Value	Change
Mario Germano Giuliani	43.82 mm	$0.00	0.0%
Achille G. Severgnini	41.65 mm	$1.07 bn	NEW
MS Morgan Stanley	41.08 mm	$1.16 tn	-6.9%
Vanguard	37.59 mm	$1.06 tn	-1.2%
FMR	27.89 mm	$789.01 bn	+0.0%
BlackRock	22.30 mm	$630.90 bn	NEW
Baillie Gifford & Co	16.12 mm	$456.11 bn	-1.4%
Viking Global Investors	12.09 mm	$342.14 bn	+1.0%
Adage Capital Partners GP, L.L.C.	11.90 mm	$336.63 bn	+8.8%
Swedbank AB	11.03 mm	$311.96 bn	+2.0%

Largest transactions	Shares	Bought/sold	Change
Achille G. Severgnini	41.65 mm	+41.65 mm	NEW
BLK BlackRock	0.00	-23.02 mm	EXIT
BlackRock	22.30 mm	+22.30 mm	NEW
JPM JPMorgan Chase & Co.	1.29 mm	-6.45 mm	-83.3%
Unisphere Establishment	0.00	-5.00 mm	EXIT
Norges Bank	0.00	-4.81 mm	EXIT
MS Morgan Stanley	41.08 mm	-3.06 mm	-6.9%
Millennium Management	4.34 mm	+1.99 mm	+84.7%
Amundi	3.69 mm	+1.63 mm	+78.8%
Deutsche Bank AG - Registered Shares	2.34 mm	+1.36 mm	+139.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RPRX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Dec 24	Bassler Bonnie L	Class A Ordinary Shares	Grant	Acquire A	No	No	24.9416	1,503	37.49 k	61,299
31 Dec 24	Henry A Fernandez	Class A Ordinary Shares	Grant	Acquire A	No	No	24.9416	1,503	37.49 k	55,505
30 Sep 24	Henry A Fernandez	Class A Ordinary Shares	Grant	Acquire A	No	No	27.9249	1,342	37.48 k	54,002
30 Sep 24	Bassler Bonnie L	Class A Ordinary Shares	Grant	Acquire A	No	No	27.9249	1,342	37.48 k	59,796
12 Aug 24	Marshall Urist	LP interests in RPI US Partners 2019, LP Class A Ordinary Shares	Gift	Dispose G	Yes	No	0	2,182	0.00	126,412

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Royalty Pharma Secures $530M From MorphoSys Bonds, Exceeding $300M 2022 Investment; Plans Share Repurchases, Royalty Acquisitions

Total proceeds of $530 million on $300 million original 2022 investmentProceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?

Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United Airlines.

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

Reported Earlier, Royalty Pharma Increases Quarterly Dividend By 5% To $0.22/Share, Payable March 10

Press releases

From Benzinga Pro

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S.

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming

Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with

Royalty Pharma Announces Dividend Increase

Royalty Pharma to Present at Upcoming Investor Conferences

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.